Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source ...

Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection pens for CagriSema, the former’s ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

These days, Novo Nordisk is reincarnating many of its spent insulin pens as office furniture like chairs and lamps. It’s an increasingly common fate for the company’s used injection devices ...

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, raising questions about which dose Novo will pursue.

Retail pharmacies are advised to purchase authentic Ozempic ® (semaglutide) injection 1 mg and other semaglutide-containing medicines through authorized distributors of Novo Nordisk.

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity therapy CagriSema. Read mkore here.

Diabeloop SA reported a partnership with Novo Nordisk A/S. The med-tech is planning to integrate DBL-4pen, its self-learning algorithm for multiple daily injection therapy, into Novo Nordisk's ...

Novo Nordisk said its price cuts would also apply to NovoLog injection pens, long-acting Levemir, intermediate-acting Novolin and several generic insulins.